CoChat

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer

Open access
Passardi, Alessandro, Scarpi, Emanuela, Cavanna, Luigi, Dall’Agata, Monia, Tassinari, Davide, Leo, Silvana, Bernardini, Ilaria, Gelsomino, Fabio, Tamberi, Stefano, Brandes, Alba A., Tenti, Elena, Vespignani, Roberto, Frassineti, Giovanni L., Amadori, Dino, De Giorgi, Ugo · 2016 · Oncotarget
Cited by 156

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Alessandro Passardi 1, * , Emanuela Scarpi 2, * , Luigi Cavanna 3 , Monia Dall’Agata 2 , Davide Tassinari 4 , Silvana Leo 5 , Ilaria Bernardini 6 , Fabio Gelsomino 7 , Stefano Tamberi 8 , Alba A. Brandes 9 , Elena Tenti 10 , Roberto Vespignani 11 , Giovanni L. Frassineti 1 , Dino Amadori 1 , Ugo De Giorgi 1 1 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 2 Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy 3 Medical Oncology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy 4 Department of Oncology, Infermi Hospital, Rimini, Italy 5 Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy 6 Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy 7 Oncology Unit, University Hospital Modena, Modena, Italy 8 Oncology Unit, Degli Infermi Hospital, Faenza, Italy 9 Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy 10 Oncology Pharmacy Laboratory, IRST IRCCS, Meldola, Italy 11 IT Service, IRST IRCCS, Meldola, Italy * These authors have contributed equally to this work Correspondence to: Emanuela Scarpi, e-mail: emanuela.scarpi@irst.emr.it Keywords: metastatic colorectal cancer, bevacizumab, SII NLR PLR, prognosis Received: February 24, 2016 Accepted: April 04, 2016 Published: April 21, 2016 ABSTRACT Background: To investigate the role of pre-treatment inflammatory indexes (II) as predictors of prognosis and treatment efficacy in patients with metastatic colorectal cancer mCRC randomized onto the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) with or without bevacizumab (Bev). Results: In the overall population, PFS and OS were higher in patients with low SII ( p = .015 and .002, respectively), low NLR ( p = .0001 and <.0001, respectively) and low PLR ( p = .004 and .008, respectively). Patients with low NLR in the CT plus Bev arm had a higher PFS than those treated with CT alone (HR = 0.69, p = .021). Patients and Methods: Two hundred and eighty-nine patients were considered for this study, 141 receiving CT plus Bev and 148 receiving CT alone. The pre-treatment systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were evaluated to identify a potential correlation with progression-free (PFS) and overall survival (OS) in both the overall population and the 2 treatment arms. Conclusion: Our results indicate that II, in particular NLR, are good prognostic and predictive markers for mCRC patients who are candidates for CT plus Bev.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.8901

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Passardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A. A., Tenti, E., Vespignani, R., Frassineti, G. L., Amadori, D., & De Giorgi, U.
Venue
Oncotarget
Published
2016-04-21
Volume
7
Issue
22
Pages
33210-33219
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2340964024
Cited by
156
References
9
FWCI
8.19
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.